Novo Nordisk Backs Unifying Ozempic, Other Drug-Harm Lawsuits

A plaintiff’s request to combine product liability litigation against Ozempic maker Novo Nordisk and Mounjaro maker Eli Lilly & Co. into a single proceeding has drawn conflicting responses from the defendant drugmakers.

Novo Nordisk supported a single proceeding while Lilly said it should be excluded from combined litigation because most of the pending suits involve its competitor’s Ozempic.

The drugs are injectable prescription medications that are used to control blood sugar in adults with type 2 diabetes. The medications have become increasingly popular for weight loss.

Louisiana resident Jaclyn Bjorklund asked the US Judicial Panel on Multidistrict Litigation in December ...